Anti-Müllerian hormone (AMH) autocrine signaling promotes survival and proliferation of ovarian cancer cells
Abstract In ovarian carcinoma, anti-Müllerian hormone (AMH) type II receptor (AMHRII) and the AMH/AMHRII signaling pathway are potential therapeutic targets. Here, AMH dose-dependent effect on signaling and proliferation was analyzed in four ovarian cancer cell lines, including sex cord stromal/gran...
Guardado en:
Autores principales: | Maëva Chauvin, Véronique Garambois, Pierre-Emmanuel Colombo, Myriam Chentouf, Laurent Gros, Jean-Paul Brouillet, Bruno Robert, Marta Jarlier, Karen Dumas, Pierre Martineau, Isabelle Navarro-Teulon, David Pépin, Thierry Chardès, André Pèlegrin |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3bb1d01d694a4347845bf86dc683698e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
PARP inhibitors promote stromal fibroblast activation by enhancing CCL5 autocrine signaling in ovarian cancer
por: Xiaoting Li, et al.
Publicado: (2021) -
Anti-Müllerian Hormone in Pathogenesis, Diagnostic and Treatment of PCOS
por: Ewa Rudnicka, et al.
Publicado: (2021) -
Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder.
por: Young H Lee, et al.
Publicado: (2021) -
Association of birth weight with functional ovarian reserve during menacme estimated by serum concentration of anti-Müllerian hormone
por: Maria L. S. Lima, et al.
Publicado: (2019) - Journal of Public Relations Research Middle East / Magallat Bhut Al-Laqat Al-Amh - Al-Srq Al-Aust